In Germany, the prospective WSG Plan B trial evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAI-1 has already recruited almost 2,500 primary breast cancer patients by early 2011[17]. This evidence concerns the gene ERBB2 and breast carcinoma.